AI Summary
✦ ClarthaValuation Metrics
Trading 0.2% above historical median. Valuation is stable — currently in the fair zone (z-score: +0.03). Confidence: 65%.
Live forward EPS implies next-12-month EPS of ₹55.40. Applying the stock's normalized valuation corridor produces a fair range of ₹171.19 to ₹277.00, with base value near ₹245.98 (+18.6% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹55.40
Forward P/E
3.7x
Base Fair Value
₹245.98
Fair Range
₹171.19 - ₹277.00
Upside To Base
+18.6%
Estimate Source
Live forward EPS
5Y Average
4.63
Current
4.45
Overvalued
5.00
Undervalued
3.09
5Y Average
4.72
Current
4.54
Overvalued
5.42
Undervalued
3.83
5Y Average
3.73
Current
3.58
Overvalued
4.28
Undervalued
3.02
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 42.8x Undervalued | -36% vs avg | +51.8% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Undervalued | -35% vs avg | -25.8% |
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -53% vs avg | +22.8% |
ASTRAZENECA PHARMA IND LT ASTRAZENPharmaceuticals | +20.4% | 8.2% | 107.1x Premium | +60% vs avg | -6.7% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 167.2x Premium | +150% vs avg | -52.5% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 27.3x Undervalued | -59% vs avg | +43.2% |
CONCORD BIOTECH LIMITED CONCORDBIOPharmaceuticals | +26.2% | 24.8% | 49.1x Undervalued | -27% vs avg | -17.2% |
SUN PHARMA ADV.RES.CO.LTD trades at a discount (4.5x vs peer avg 66.9x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include AKUMS DRUGS AND PHARMA L, BLUE JET HEALTHCARE LTD, CAPLIN POINT LAB LTD. — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹8.45 CrDec 2025Latest net profit
₹-68 CrDec 2025Latest EPS
₹-2.48Dec 2025Net margin
-703.3%Dec 2025Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Dec 2025
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 47.69 | 23.95 | 21.18 | 13.86 | 16.56 | 16.81 | 12.86 | 14.91 | 27.19 | 9.64 | 7.86 | 8.45 |
| Expenses | 137 | 126 | 113 | 116 | 124 | 110 | 117 | 89.29 | 81.11 | 61.97 | 73.75 | 65.32 |
| Operating Profit | -92.51 | -105 | -94.65 | -106 | -110 | -96.5 | -107 | -77.13 | -56.47 | -54.87 | -68.46 | -59.43 |
| OPM % | -193.98% | -439.58% | -446.88% | -763.2% | -665.52% | -574.06% | -829.08% | -517.3% | -207.69% | -569.19% | -870.99% | -703.31% |
| Other Income | 10.73 | 10.19 | 8.49 | 6.39 | 4.4 | 1.56 | 0.04 | 0.19 | — | 9.02 | 0.01 | — |
| Interest | 0.21 | 0.26 | 0.26 | 0.26 | 0.88 | 0.56 | 1.11 | 2.77 | 4.51 | 6.18 | 7.52 | 8.78 |
| Depreciation | 2.94 | 3.1 | 3.18 | 3.16 | 2.69 | 3.14 | 2.77 | 2.75 | 2.55 | 2.54 | 2.57 | 2.56 |
| Profit before tax | -81.99 | -95.35 | -86.42 | -99.65 | -107 | -95.5 | -108 | -79.71 | -60.98 | -52.03 | -75.97 | -68.21 |
| Tax % | 0% | 0% | 0% | 0% | 0% | -0.42% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -81.99 | -95.35 | -86.42 | -99.65 | -107 | -95.9 | -108 | -79.71 | -60.98 | -52.03 | -75.97 | -68.21 |
| EPS in Rs | -2.55 | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 | -3.32 | -2.46 | -1.88 | -1.60 | -2.34 | -2.48 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.